Brigatinib for ALK-positive metastatic non-small-cell lung cancer: Design, development and place in therapy

Robert Ali, Junaid Arshad, Sofia Palacio, Raja Mudad

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.

Original languageEnglish (US)
Pages (from-to)569-580
Number of pages12
JournalDrug design, development and therapy
Volume13
DOIs
StatePublished - 2019

Keywords

  • ALK inhibitors
  • ALK positive
  • Brigatinib
  • Non-small cell lung cancer
  • TKI

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Brigatinib for ALK-positive metastatic non-small-cell lung cancer: Design, development and place in therapy'. Together they form a unique fingerprint.

  • Cite this